Abstract
WHAT IS KNOWN AND OBJECTIVE Vismodegib is indicated in patients with symptomatic metastatic basal cell carcinoma (BCC) or locally advanced BCC when surgery or radiotherapy are not appropriate. The significant efficacy of vismodegib in responding patients and lack of therapeutic alternatives are counterbalanced by intolerance and severe adverse events (AEs), leading to discontinuation in 30% of patients. We aimed to evaluate the relationship between vismodegib pharmacokinetics (PK) and occurrence of AEs, and to investigate the association between concentrations and response in terms of efficacy.
RESULTS Mean of trough vismodegib plasma concentrations ranged from 3.9 mg/L to 30 mg/L per patient, with an overall mean of 11.8 (± 5) mg/L. A high correlation between total vismodegib and alpha-1 acid glycoprotein (AAG) levels was observed (Spearman’s ρ = 0.6733, p-value =1.662e-12). Inter-individual variability was significant (CV% of 42%).
Patients with stable and progressive disease had a significantly higher median vismodegib plasma concentration than those with partial and complete response (p = 0.03).
Tumor volume ranged from 0 to 12 292 135 mm3 in our cohort. Mean tumor volume slope was -1187.97 (± 9734).
WHAT IS KNEW AND CONCLUSION We explored PK/pharmacodynamic (PD) relationships of vismodegib in patients with BCC. This is the first study which reported PK data obtained in BCC patients treated with vismodegib in a real-life clinical practice.
Our study confirmed the strong influence of AAG levels on vismodegib protein binding. Concerning the PK/PD relationship evaluation, we notably observed that patients with the lowest plasma concentrations respond best to treatment. Our mathematical estimation of tumor volume showed that between the beginning and the end of the study, tumor growth was positively correlated to vismodegib levels, which was in line with the correlation observed for efficacy/safety data.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT03610022
Clinical Protocols
https://classic.clinicaltrials.gov/ct2/show/study/NCT03610022?term=optivismo&draw=2&rank=1
Funding Statement
This study was funded by University Hospital of Bordeaux (France)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Ethics committee of CHU de Bordeaux anad registered under the number CHUBX 2017/41, and has the ID number NCT03610022 (Relationship Between Pharmacokinetics and Safety of Vismodegib - OPTIVISMO-1 (OPTIVISMO-1)) on ClinicalTrial.gov The sponsor is University Hospital Bordeaux
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
